KMT2A and acute lymphoblastic leukemia: Indeed, the current ongoing clinical trial of using azacitidine and combination chemotherapy to treat infants who have acute lymphoblastic leukemia and rearrangements in the methyltransferase-encoding gene KMT2A (NCT02828358; https://clinicaltrials.gov/ct2/show/NCT02828358).